Edoxaban

	WikiDoc Resources for Edoxaban
Articles
Most recent articles on Edoxaban Most cited articles on Edoxaban Review articles on Edoxaban Articles on Edoxaban in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Edoxaban Images of Edoxaban Photos of Edoxaban Podcasts & MP3s on Edoxaban Videos on Edoxaban
Evidence Based Medicine
Cochrane Collaboration on Edoxaban Bandolier on Edoxaban TRIP on Edoxaban
Clinical Trials
Ongoing Trials on Edoxaban at Clinical Trials.gov Trial results on Edoxaban Clinical Trials on Edoxaban at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Edoxaban NICE Guidance on Edoxaban NHS PRODIGY Guidance FDA on Edoxaban CDC on Edoxaban
Books
Books on Edoxaban
News
Edoxaban in the news Be alerted to news on Edoxaban News trends on Edoxaban
Commentary
Blogs on Edoxaban
Definitions
Definitions of Edoxaban
Patient Resources / Community
Patient resources on Edoxaban Discussion groups on Edoxaban Patient Handouts on Edoxaban Directions to Hospitals Treating Edoxaban Risk calculators and risk factors for Edoxaban
Healthcare Provider Resources
Symptoms of Edoxaban Causes & Risk Factors for Edoxaban Diagnostic studies for Edoxaban Treatment of Edoxaban
Continuing Medical Education (CME)
CME Programs on Edoxaban
International
Edoxaban en Espanol Edoxaban en Francais
Business
Edoxaban in the Marketplace Patents on Edoxaban
Experimental / Informatics
List of terms related to Edoxaban

Edoxaban
Clinical data
Trade names	Lixiana
ATC code	none;
Identifiers
	IUPAC name N'-(5-chloropyridin-2-yl)-N-[(1S,2R,4S)-4-(dimethylcarbamoyl)-2-[(5-methyl-6,7-dihydro-4H-[1,3]thiazolo[5,4-c]pyridine-2-carbonyl)amino]cyclohexyl]oxamide;
CAS Number	912273-65-5 ;
PubChem CID	25022378;
UNII	NDU3J18APO;
KEGG	D09710 ;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C24H30ClN7O4S
Molar mass	548.056 g/mol
(what is this?) (verify)

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Edoxaban (INN, codenamed DU-176b, trade name Lixiana) is an anticoagulant drug which acts as a direct factor Xa inhibitor. It is being developed by Daiichi Sankyo. It was approved in July 2011 in Japan for prevention of venous thromboembolisms (VTE) following lower-limb orthopedic surgery.^[1]

Preclinical Research

In animal studies, edoxaban is potent, selective for factor Xa and has good oral bioavailability.^[2]

Clinical Trials

Several Phase II clinical trials have been conducted, for example for thromboprophylaxis after total hip replacement^[3] (phase III early results compare well to enoxaparin^[4]), and for stroke prevention in patients with atrial fibrillation^[5] (phase III has completed enrollment^[4]).

A large phase III trial showed that edoxaban was non inferior to warfarin in preventing recurrent venous thromboembolic events with fewer episodes of major bleeding.^[6] This paper follows similar recent major trials showing similar results for the other new factor Xa inhibitors, rivaroxaban and apixaban.^[5]

References

↑ "First market approval in Japan for LIXIANA (Edoxaban)". Press Release. Daiichi Sankyo Europe GmbH. 2011-04-22.
↑ Furugohri T, Isobe K, Honda Y, Kamisato-Matsumoto C, Sugiyama N, Nagahara T, Morishima Y, Shibano T (September 2008). "DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles". J. Thromb. Haemost. 6 (9): 1542–9. doi:10.1111/j.1538-7836.2008.03064.x. PMID 18624979.
↑ PMID 20589317
↑ ^4.0 ^4.1 "Phase III Trial Finds Edoxaban Outclasses Enoxaparin in Preventing Venous Thromboembolic Events". 8 Dec 2010.
↑ ^5.0 ^5.1 Weitz JI, Connolly SJ, Patel I, Salazar D, Rohatagi S, Mendell J, Kastrissios H, Jin J, Kunitada S (September 2010). "Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation". Thromb. Haemost. 104 (3): 633–41. doi:10.1160/TH10-01-0066.
↑ "Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism". N. Engl. J. Med. August 2013. doi:10.1056/NEJMoa1306638. PMID 23991658.

[url_Daiichi_Sankyo_Europe_GmbH-1] "First market approval in Japan for LIXIANA (Edoxaban)". Press Release. Daiichi Sankyo Europe GmbH. 2011-04-22.

[pmid18624979-2] Furugohri T, Isobe K, Honda Y, Kamisato-Matsumoto C, Sugiyama N, Nagahara T, Morishima Y, Shibano T (September 2008). "DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles". J. Thromb. Haemost. 6 (9): 1542–9. doi:10.1111/j.1538-7836.2008.03064.x. PMID 18624979.

[3] PMID 20589317

[Dec2010-4] 4.0 ^4.1 "Phase III Trial Finds Edoxaban Outclasses Enoxaparin in Preventing Venous Thromboembolic Events". 8 Dec 2010.

[pmid-5] 5.0 ^5.1 Weitz JI, Connolly SJ, Patel I, Salazar D, Rohatagi S, Mendell J, Kastrissios H, Jin J, Kunitada S (September 2010). "Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation". Thromb. Haemost. 104 (3): 633–41. doi:10.1160/TH10-01-0066.

[pmid23991658-6] "Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism". N. Engl. J. Med. August 2013. doi:10.1056/NEJMoa1306638. PMID 23991658.

[1]

[2]

[3]

[4]

[5]

[6]

Edoxaban

Overview

Preclinical Research

Clinical Trials

References

Navigation menu